Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

NCT03282227 is registered in ClinicalTrials.gov with Zosano Pharma Corporation as lead sponsor.

NCT NCT03282227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03282227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Lead sponsor
Zosano Pharma Corporation
Phase
Phase 3
Overall status
Completed
Start date
November 7, 2017
Completion date
May 17, 2019
Enrollment
342 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

migraine